Partner identification and deal-making
Accurately benchmark industry investments and generate the maximum value for your assets.
Position your deals to achieve maximum return
Access the industry’s most complete deals database, including early-phase pipeline assets and start-up companies. Get to the information you need faster with precise indexing, customizable and exportable analyses, and time-saving visualizations.
Find your ideal partner
Identify opportunities based on your ideal candidate’s characteristics or gaps in their portfolio, and explore potential partners’ deal history including payment terms.
Accurately value an asset
Use AI-based predictive analytics to predict potential deal sizes at each stage of drug development and uncover how likely it would be for a drug to progress to the next phase of development if you were to partner.
Complete due diligence within minutes
Prepare for negotiations with the most comprehensive deals coverage, including deal comps and unredacted contracts.
Monitor industry investment
Benchmark drug and therapy area financing with an in-depth view of the investment activity of new therapies, linking financing activity, drug, company, stage, and transaction activity.
Partner identification and deal-making
150k+
35k+
283k+
10k+
Resources
Deal making in uncertain times
With loss of exclusivity looming for some of the best-selling drugs, pharma companies are going to have to find new sources of revenue to backfill. A glance at the 2022 best selling drugs demonstrates how reliant many pharma companies are on external innovation (e.g. Humira, Comirnaty, Keytruda). Until recently, the availability of capital facilitated the...
